What has caused a paradigm shift in the approach to treatment of non–small cell lung cancer (NSCLC)?

Updated: Jul 15, 2021
  • Author: Winston W Tan, MD, FACP; Chief Editor: Nagla Abdel Karim, MD, PhD  more...
  • Print

The treatment of NSCLC has drastically changed over the past few years, with the advent of molecular-targeted agents. Nevertheless, cytotoxic chemotherapy retains a role in management..

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!